Organon & Co. (NYSE:OGN) Q4 2023 Earnings Conference Call February 15, 2024 8:30 AM ET Company Participants Jennifer Halchak - Vice President of Investor Relations Kevin Ali - CEO & Director Matthew Walsh - Executive VP & CFO Conference Call Participants Umer Raffat - Evercore ISI Jason Gerberry - Bank of America Navann Ty - BNP Paribas Balaji Prasad - Barclays Christopher Schott - JPMorgan Karishma Raghuram - Goldman Sachs Operator Thank you for standing by. And welcome to the Organon Q4 Full Year 2023 Ear ...

Organon Fourth Quarter and Full Year 2023 Earnings Cautionary Note Regarding Forward-Looking Statements Except for historical information, this presentation includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management's expectations about Organon's future financial performance and prospects, including full-year 2024 guidance estimates and predictions regarding ot ...

Organon & Co. (NYSE:OGN) JPMorgan 42nd Annual Healthcare Conference Call January 9, 2024 4:30 PM ET Company Participants Kevin Ali - Chief Executive Officer Matt Walsh - Chief Financial Officer Conference Call Participants Christopher Schott - JPMorgan Christopher Schott Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it is my pleasure to be hosting this fireside chat with the Organon management today. From the company, we have CEO, Kevin Ali; as well as CFO, Matt Walsh. Kevin and Matt, Happy N ...

Organon & Co (NYSE:OGN) Piper Sandler 35th Annual Healthcare Conference November 29, 2023 11:00 AM ET Company Participants Kevin Ali - Chief Executive Officer Matthew Walsh - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler David Amsellem Okay. Good morning, everyone, and let's get started. Welcome again to the 35th Annual Piper Sandler Healthcare Conference. I'm David Amsellem from the pharma team. And with us is Organon. We have Kevin Ali, CEO; and Matt Walsh, CFO. Thank ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 10-Q ________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File No. 001-40235 Organon & Co. (Exact name of registrant as specifi ...

Organon & Co (NYSE:OGN) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matthew Walsh - CFO Sandra Milligan - Head of R&D Conference Call Participants Navann Ty - Exane BNP Paribas David Amsellem - Piper Sandler Bhavin Patel - Bank of America Roger Xu - Goldman Sachs Mikaela Franceschina - Barclays Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Organon Third Quarter 2 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 10-Q ________________ (Mark One) | | | For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File No. 001-40235 Organon & Co. (Exact name of registrant as specified in its charter) Delaware 46-4838035 (State or other jurisdiction of incorporation) (I. ...

Organon & Co (NYSE:OGN) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matthew Walsh - CFO Sandra Milligan - Head of R&D Conference Call Participants David Amsellem - Piper Sandler Umer Raffat - Evercore Jason Gerberry - Bank of America Navann Ty - BNP Paribas Exxon Chris Shibutani - Goldman Sachs Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Organon Second Quarter 202 ...

Organon Second Quarter 2023 Earnings GANON™ Cautionary Note Regarding Forward-Looking Statements Disclaimer statement, cont. See Slides 21-26 of this presentation for a reconciliation of non-GAAP measures. • Adjusted EBITDA of $530 million • Adjusted EBITDA margin guidance range raised to 31.5%-33.0% Disclaimer statement Risks and uncertainties include, but are not limited to, an inability to fully execute on our product development and commercialization plans within the United States or internationally; ch ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 10-Q ________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File No. 001-40235 Organon & Co. (Exact name of registrant as specified in its charter) Del ...